Susan Veldhof

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

• Gogas B,
• Bourantas C,
• Garcia-Garcia H,
• Onuma Y,
• Muramatsu T,
• Farooq V,
• Diletti R,
• van Geuns R-J,
• De Bruyne B,
• Chevalier B,
• Thuesen L,
• Smits P,
• Dudek D,
• Koolen J,
• Windecker S,
• Whitbourn R,
• McClean D,
• Dorange C,
• Miquel-Hebert K,
• Veldhof S,
• Rapoza R,
• Ormiston J,
• Serruys PW

EuroIntervention 2013; 8-online publish-ahead-of-print April 2013

Published ahead of print on April 30, 2013

Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

• Gomez-Lara J,
• Diletti R,
• Brugaletta S,
• Onuma Y,
• Farooq V,
• Thuesen L,
• McClean D,
• Koolen J,
• Ormiston J,
• Windecker S,
• Whitbourn R,
• Dudek D,
• Dorange C,
• Veldhof S,
• Rapoza R,
• Regar E,
• García-García HM,
• Serruys PW

EuroIntervention 2012;8:214-224

Published in Volume 8 Number 2, June 2012

A six-month analysis of quantitative echogenicity of the second generation everolimus-eluting bioresorbable vascular scaffold in relationship with baseline greyscale intravascular ultrasound morphology of the scaffolded plaque

• Brugaletta S,
• Serruys PW,
• Ormiston J,
• Gomez-Lara J,
• Farooq V,
• van Geuns R-J,
• de Bruyne B,
• Dudek D,
• Thuesen L,
• Chevalier B,
• McClean D,
• Windecker S,
• Whitbourn R,
• Veldhof S,
• Miquel-Hebert K,
• Rapoza R,
• van Domburg R,
• Sihan K,
• de Winter S,
• García-García HM,
• Bruining N

Published in Volume 7 Supplement M, May 2011

Angiographic geometric changes of the lumen vessel wall after bioresorbable vascular scaffolds and metallic platform stents at one-year follow-up

• Gomez-Lara J,
• Brugaletta S,
• Farooq V,
• van Geuns R-J,
• de Bruyne B,
• Windecker S,
• McClean D,
• Thuesen L,
• Dudek D,
• Koolen J,
• Whitbourn R,
• Smits P,
• Chevalier B,
• Morel M-A,
• Dorange C,
• Veldhof S,
• Rapoza R,
• García-García HM,
• Ormiston J

Published in Volume 7 Supplement M, May 2011

Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study

• Brugaletta S,
• García-García HM,
• Diletti R,
• Gomez-Lara J,
• Garg S,
• Onuma Y,
• Shin E,
• van Geuns R-J,
• de Bruyne B,
• Dudek D,
• Thuesen L,
• Chevalier B,
• McClean D,
• Windecker S,
• Whitbourn R,
• Dorange C,
• Veldhof S,
• Rapoza R,
• Sudhir K,
• Bruining N,
• Ormiston J,
• Serruys PW

EuroIntervention 2011;6:1110-1116

Published in Volume 6 Number 9, April 2011

Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial

• Onuma Y,
• Serruys PW,
• Ormiston J,
• Regar E,
• Webster M,
• Thuesen L,
• Dudek D,
• Veldhof S,
• Rapoza R

EuroIntervention 2010;6:447-453 published online ahead of print June 2010

Published in Volume 6 Number 4, September 2010

Conformability of bioresorbable Everolimus-eluting scaffolds as compared to metal platform stents

• Gomez-Lara J,
• García-García HM,
• Onuma Y,
• Thuesen L,
• Dudek D,
• Garg S,
• de Bruyne B,
• Windecker S,
• Chevalier B,
• Smits P,
• McClean DR,
• Koolen J,
• Whitbourn R,
• Veldhof S,
• Dorange C,
• Ormiston J,
• Serruys PW

Published in Volume 6 Supplement H, May 2010

A pooled gender based analysis comparing the XIENCE V® everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis

• Seth A,
• Serruys PW,
• Lansky A,
• Hermiller J,
• Onuma Y,
• Miquel-Hebert K,
• Yu S,
• Veldhof S,
• Sood P,
• Sudhir K,
• Stone G

EuroIntervention 2010;5:788-794

Published in Volume 5 Number 7, February 2010

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study

• Ruygrok P,
• Desaga M,
• van den Branden F,
• Rasmussen K,
• Suryapranata H,
• Dorange C,
• Veldhof S,
• Serruys PW

EuroInterv.2007;3:315-320

Published in Volume 3 Number 3, November 2007

Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial)

• Beijk M,
• Neumann F-J,
• Wiemer M,
• Grube E,
• Haase J,
• Thuesen L,
• Hamm C,
• Veldhof S,
• Dorange C,
• Serruys PW,
• Piek J

EuroInterv.2007;3:206-212

Published in Volume 3 Number 2, August 2007

One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings
(The SPIRIT FIRST Trial)

• Tsuchida K,
• Piek J,
• Neumann F-J,
• van der Giessen WJ,
• Wiemer M,
• Zeiher A,
• Grube E,
• Haase J,
• Thuesen L,
• Hamm C,
• Veldhof S,
• Dorange C,
• Serruys PW

EuroInterv.2005;1:266-272

Published in Volume 1 Number 3, November 2005